MNPR · Monopar Therapeutics Inc. · Stock research

Current Thesis

Since the 2026-08-15 note the stock printed a fresh 52-week high at $123.84, then gave it back: the 2026-08-21 close was $107.72, 13.0% under that high, with RSI(14) at 46.0. No company release explains the reversal — the most recent corporate news, on 2026-08-19, was the appointment of Jeffrey D. Kent, M.D. as EVP, Head of Medical Affairs plus two ALXN1840 presentations accepted for AASLD The Liver Meeting 2026, and the tape closed lower into 2026-08-21 anyway. The narrative an investor is buying is unchanged from July: finish the rolling NDA started 2026-07-22, clear the FDA's filing decision, reach approval with a transferable rare-pediatric-disease Priority Review Voucher attached. What changed is the composition of the bid. The sell-side finished repricing in the 2026-08-12 → 2026-08-16 window and now sits at a consensus 12-month target of $126.31 across 13 analysts, so the marginal buyer at $107.72 is paying for a regulatory outcome with no dated event inside the next 30 days.

Bullish and bearish views on Monopar Therapeutics Inc.

The model's bull view on Monopar Therapeutics Inc. (MNPR), in brief: 2026-07-22: FDA authorized a rolling NDA for ALXN1840 in Wilson disease and the first completed sections were submitted. The bear view: The new high was rejected. $123.84 was reached and sold inside the same stretch that produced four target changes; RSI(14) has slid from 53.3 on 2026-08-14 to 46.0 on 2026-08-21. Momentum is neutral for the first time since the July leg started. The sell-side has caught up to… Both cases follow in full.

Bull Case

• 2026-07-22: FDA authorized a rolling NDA for ALXN1840 in Wilson disease and the first completed sections were submitted. The regulatory clock is live rather than promised.
• 2026-08-12 business update: completion of the submission anticipated "within the next few months."
• 2026-08-19: Kent hired as EVP, Head of Medical Affairs, and two ALXN1840 presentations announced for AASLD The Liver Meeting 2026 (2026-11-05 to 2026-11-09, Denver). Medical-affairs build-out and a hepatology-congress slot are the spending pattern of a company preparing to launch, following the Chief Commercial and Strategy Officer hired in March 2026.
• Funded past the decision: cash, cash equivalents and investments were $134.3M at 2026-06-30, runway guided through at least 2027-12-31 including regulatory and potential commercial activities.
• Voucher optionality is statutorily live: the Consolidated Appropriations Act of 2026, signed 2026-02-03, §6604, extends FDA authority to issue rare pediatric disease PRVs through 2029-09-30; ALXN1840's RPD designation was granted in June 2026.
• Target stack still sits above the last close: BTIG $133 (2026-08-12), Morgan Stanley $130 raised from $115 (mid-August 2026), Barclays $128 (2026-08-13), HC Wainwright $125 (2026-07-22), Cantor $119 (2026-08-13).
• The clinical package is built and presented: Phase 3 FoCus met its primary (daily copper-mobilization AUEC over 48 weeks); AAN April 2026 showed neurologic worsening 9% versus 25% on standard of care; EAN 2026-06-26 reported UWDRS Part III p=0.006.
• The $107.72 close remains above the $105.00 pre-June 52-week high — the June/July re-rating shelf has not been surrendered.

Bear Case

• The new high was rejected. $123.84 was reached and sold inside the same stretch that produced four target changes; RSI(14) has slid from 53.3 on 2026-08-14 to 46.0 on 2026-08-21. Momentum is neutral for the first time since the July leg started.
• The sell-side has caught up to the price. A consensus target of $126.31 against a $107.72 close leaves roughly a sixth of upside on the street's own numbers, and the highest published figure is $133. Further re-rating needs new facts, not new targets.
• The first ratings step-downs of the run landed 2026-08-13: Cantor Fitzgerald to Neutral, and Zacks Research from Strong Buy to Hold per the ratings feed.
• The 2026-08-19 release did not buy a new bid. A senior hire plus two congress abstracts is the kind of news that moves a thin-float name; it did not.
• Rolling is not filed. The FDA's 60-day filing decision only begins when the final module arrives, so refuse-to-file risk is deferred. FoCus's primary was a copper-mobilization biomarker (dNCC AUEC), which remains the objection an agency oriented to hard clinical outcomes can raise.
• "Within the next few months" still has no calendar entry more than a month after it was said, and Q2 was reported 2026-08-12, so no scheduled company event falls inside 30 days.
• Q2 2026 economics: net loss $5.3M, or $(0.62) per share, versus $2.5M / $(0.35) in Q2 2025; R&D $4,766,832 versus $1.73M a year earlier.
• Float mechanics cut both ways. Shares outstanding are 6.71M against a $723.04M market cap; the same structure that produced a 70.7% three-month advance thins out on the way back.

Setup & Price Structure

• Reference close 2026-08-21: $107.72. 52-week high $123.84 (a new high since the prior note's $120.21), 13.0% below it. RSI(14) 46.0. The shares are up 70.7% over three months, down from 90.7% measured on 2026-08-14.
• The week made a higher high and a lower close than the prior note's $113.04 — the definition of a distribution week in a name that had not had one since 2026-07-22.
• Two structural references below: $105.00, the pre-June 52-week high, is the shelf the June/July re-rating built off; $100 round-trips the entire post-rolling-NDA leg.
• The narrative is maturing. Dating it — attention peaked in the 2026-08-12/13 cluster (Q2 print, BTIG $133, Barclays $128, Cantor's downgrade, Zacks to Hold), Morgan Stanley followed to $130 by mid-August, and the 2026-08-19 corporate release drew no new high. The story still works (price above the pre-June shelf, balance sheet funded, submission clock running) but the incremental flow is moderating. A flip to saturated would be dated by several weeks of failing to reclaim $123.84 while the published target range stays $119–$133.
• Crowding observables, stated as observables: 13 covering analysts with a Strong Buy consensus and a $126.31 average target as retrieved 2026-08-23; four target changes inside five sessions; 6.71M shares outstanding; no earnings date inside 30 days; no new company filings surfaced since the 2026-08-12 Q2 release in the feed reviewed for this note.

Catalyst Calendar (next 30 days)

• No dated company or regulatory event falls between 2026-08-23 and 2026-09-22. That absence is itself the near-term condition: the price has to hold on flow alone.
• ~2026-10-31 (est.) — completion of the rolling NDA submission. The estimate reads the "within the next few months" phrase used on 2026-08-12; it is not guidance.
• ~60 days after completion (est.) — FDA filing decision: acceptance for review versus refuse-to-file.
• 2026-11-05 to 2026-11-09 — AASLD The Liver Meeting 2026, Denver. Two ALXN1840 presentations announced 2026-08-19.
• ~2026-11-12 (est.) — Q3 2026 results: checkpoint on submission timing, the R&D step-up, and the through-2027 runway language.

What Would Change Our Mind

The structure that matters is the June/July re-rating shelf, and the level that voids it is a weekly close below $100 — that erases the entire move built on the 2026-07-22 rolling-submission news and puts price under the $105.00 pre-June 52-week high, at which point the regulatory clock is being valued at less than it was before the FDA authorized the rolling filing. Secondary conditions, any of which would break the frame independently: the submission still incomplete when Q3 results land (~2026-11-12, est.) or timing language softened in that release; an FDA refuse-to-file letter or an acceptance carrying an advisory-committee requirement; an S-3, ATM or marketed follow-on priced near record levels despite runway guided through 2027-12-31. On the other side, reclaiming $123.84 on a weekly close, or a completion-of-submission press release, would restore the accelerating read this note is stepping back from.

Correlation Notes

• Idiosyncratic regulatory single-asset story: day-to-day correlation to small-cap biotech beta (XBI) is real for risk appetite, but the resolving events are company-specific and unhedgeable by index exposure.
• The PRV component is policy-linked. Voucher value depends on FDA's authority running to 2029-09-30 under CAA 2026 §6604 and on the secondary market for vouchers; any legislative change re-prices the whole rare-pediatric cohort at once, not just this name.
• With 6.71M shares outstanding, index-rebalance and passive flows can dominate fundamental news on any given session, which is why weekly closes carry more structural information here than intraday ranges.
• Competing Wilson disease programs, including gene-therapy approaches from other sponsors, share the same commercial pool; a pivotal readout elsewhere compresses the duration an approved ALXN1840 would enjoy.